button bars forest bayes pooled summary circles
 
DCR

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus BSC
durvalumab plus tremelimumab vs. BSC 1 1613 [637; 2589] /10000
27/119 vs. 4/61
versus regorafenib
atezolizumab alone vs. regorafenib 1 -
atezolizumab plus cometinib vs. regorafenib 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons